pidilizumab

mAbexperimental

Pidilizumab is a monoclonal antibody being developed by Medivation for the treatment of cancer and infectious diseases. Pidilizumab was originally thought to bind to the PD-1 immune checkpoint molecule, however, recent evidence suggests that Delta-like 1 (DLL1) is its primary binding target while binding to PD-1 is secondary and restricted to non-glycosylated and hypoglycosylated forms of this molecule. Pidilizumab causes in the attenuation of apoptotic processes in lymphocytes, primarily effector/memory T cells. — Wikipedia

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • ct-011
  • ct-011
  • ct-011
  • mdv9300
  • pidilizumab
  • pidilizumab

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02653989Phase 2Dec 1, 2016Medivation
NCT02530125Phase 2Sep 1, 2015Gateway for Cancer Research, National Cancer Institute (NCI), Northwestern University
NCT02077959Phase 1/Phase 2 (Phase 2)Mar 3, 2014CureTech Ltd, Ohio State University
NCT01952769Phase 1/Phase 2 (Phase 2)Feb 1, 2014Hebrew University
NCT01420965Phase 2Sep 1, 2012Augusta University
NCT01313416Phase 2Sep 1, 2012Augusta University
NCT01435369Phase 2Nov 1, 2011Harvard University, Medivation
NCT01441765Phase 2Nov 1, 2011Harvard University, National Cancer Institute (NCI), National Institutes of Health (NIH)
NCT01386502Phase 1Jun 15, 2011National Cancer Institute (NCI)
NCT01067287Phase 2Mar 1, 2010Department of Defense, Gateway for Cancer Research, Harvard University, Technion University
NCT00904722Phase 2Jan 1, 2010CureTech Ltd, University of Texas at Houston
NCT00966251Phase 1/Phase 2 (Phase 2)Oct 1, 2009CureTech Ltd, Hebrew University, Teva
NCT00962936Phase 1/Phase 2 (Phase 2)Sep 1, 2009CureTech Ltd, Hebrew University, Teva
NCT00890305Phase 2May 1, 2009Cornell University, Medivation
NCT00532259Phase 2Oct 1, 2007CureTech Ltd, Northwestern University, Tel Aviv University
Showing 15 of 15 trials
Page 1 / 1

Organizations

Research & Development (16)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
CureTech LtdFor profit5312007
Harvard UniversityAcademic/Hospital3212010
Hebrew UniversityAcademic/Hospital3112009
MedivationFor profit3312009
National Cancer Institute (NCI)Government3122011
Augusta UniversityAcademic/Hospital2212012
Gateway for Cancer ResearchAcademic/Hospital2012010
Northwestern UniversityAcademic/Hospital2112007
TevaFor profit2012009
Cornell UniversityAcademic/Hospital1012009
Department of DefenseGovernment1012010
National Institutes of Health (NIH)Government1012011
Ohio State UniversityAcademic/Hospital1112014
Technion UniversityAcademic/Hospital1012010
Tel Aviv UniversityAcademic/Hospital1012007
University of Texas at HoustonAcademic/Hospital1112010
16 organizations
Page 1 / 1